Page last updated: 2024-10-19

niacin and HIV Coinfection

niacin has been researched along with HIV Coinfection in 27 studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Research Excerpts

ExcerptRelevanceReference
"Pellagra is a clinical syndrome caused by a deficiency of niacin (nicotinic acid) and/or its precursor tryptophan."9.12Pellagra a review exploring causes and mechanisms, including isoniazid-induced pellagra. ( Dawe, RS; Mponda, K; Prabhu, D, 2021)
"Pellagra is caused by niacin (vitamin B3) deficiency and patients with pellagra present with a characteristic rash."8.12Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. ( Auld, AF; Buono, N; Chilikutali, L; Chisuwo, L; Chiwaula, MJ; da Silva, R; Girma, B; Gunde, LJ; Gutreuter, S; Jahn, A; Kalua, T; Kaunda, E; Kim, EJ; Kumwenda, T; Maida, A; Maphosa, T; Marshall, RE; Mbewe, K; Mekonnen, TF; Melgar, M; Mhango, V; Moffitt, A; Mponda, K; Mtoto, F; Muula, AS; Mwamale, S; Mwenyeheri, G; Nabity, SA; Nagoli, E; Ngongonda, D; Nyirenda, R; Odo, M; Oeltmann, JE; Sharma, AJ; Sunguti, J; Surie, D; Williams, AM; Woelk, G; Zimba, SB, 2022)
"Niacin or tryptophan deficiency causes pellagra."8.02A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report. ( Kabengele, C; M'hango, H; Malumani, M; Mweemba, D, 2021)
"Pellagra is a clinical syndrome caused by a deficiency of niacin (nicotinic acid) and/or its precursor tryptophan."5.12Pellagra a review exploring causes and mechanisms, including isoniazid-induced pellagra. ( Dawe, RS; Mponda, K; Prabhu, D, 2021)
"Pellagra is caused by niacin (vitamin B3) deficiency and patients with pellagra present with a characteristic rash."4.12Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. ( Auld, AF; Buono, N; Chilikutali, L; Chisuwo, L; Chiwaula, MJ; da Silva, R; Girma, B; Gunde, LJ; Gutreuter, S; Jahn, A; Kalua, T; Kaunda, E; Kim, EJ; Kumwenda, T; Maida, A; Maphosa, T; Marshall, RE; Mbewe, K; Mekonnen, TF; Melgar, M; Mhango, V; Moffitt, A; Mponda, K; Mtoto, F; Muula, AS; Mwamale, S; Mwenyeheri, G; Nabity, SA; Nagoli, E; Ngongonda, D; Nyirenda, R; Odo, M; Oeltmann, JE; Sharma, AJ; Sunguti, J; Surie, D; Williams, AM; Woelk, G; Zimba, SB, 2022)
"Niacin or tryptophan deficiency causes pellagra."4.02A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report. ( Kabengele, C; M'hango, H; Malumani, M; Mweemba, D, 2021)
"Pellagra is a systemic disorder caused by severe niacin deficiency."3.70[Prevalence of HIV infection in patients with pellagra and pellagra-like erythemas]. ( Kombate, K; Pitche, P; Tchangai-Walla, K, 1999)
"Niacin was well-tolerated."2.72Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. ( Aberg, JA; Alston-Smith, BL; Deeg, MA; Dubé, MP; Greenwald, M; Lee, D; Martinez, AI; McGovern, ME; Shriver, SL; Stein, JH; Wu, JW, 2006)
"ER-niacin's role in the treatment of antiretroviral therapy-associated dyslipidemia requires further evaluation, but the results of this pilot study indicate that it is safe and tolerated and provides a valuable treatment option."2.71Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. ( Claxton, S; DeMarco, D; Drechsler, H; Gerber, MT; Mondy, KE; Powderly, WG; Stoneman, J; Tebas, P; Yarasheski, KE, 2004)
"Niacin has recently been demonstrated to lower blood pressure in hypertensive patients and to reduce cardiovascular events when combined with a statin."2.47Pellagra: a review with emphasis on photosensitivity. ( Anstey, A; Moat, S; Wan, P, 2011)
"Lipodystrophy is defined as the defective metabolism of fat, and it is characterized by distinct physical changes, such as an increased waist size or an accumulation of fatty tissue at the base of the neck."1.30Update on lipodystrophy. ( Gaucher, M, 1999)

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (11.11)18.2507
2000's6 (22.22)29.6817
2010's14 (51.85)24.3611
2020's4 (14.81)2.80

Authors

AuthorsStudies
Nabity, SA1
Mponda, K2
Gutreuter, S1
Surie, D1
Zimba, SB1
Chisuwo, L1
Moffitt, A1
Williams, AM1
Sharma, AJ1
Marshall, RE1
Chiwaula, MJ1
da Silva, R1
Kumwenda, T1
Chilikutali, L1
Mwamale, S1
Nagoli, E1
Mwenyeheri, G1
Ngongonda, D1
Kaunda, E1
Mtoto, F1
Mhango, V1
Mbewe, K1
Melgar, M1
Odo, M1
Jahn, A1
Buono, N1
Maida, A1
Girma, B1
Kalua, T1
Nyirenda, R1
Sunguti, J1
Woelk, G1
Gunde, LJ1
Mekonnen, TF1
Maphosa, T1
Kim, EJ1
Auld, AF1
Muula, AS1
Oeltmann, JE1
Lebouché, B2
Yero, A1
Shi, T1
Farnos, O1
Singer, J2
Kema, I1
Costiniuk, CT1
Thomas, R2
Brouillette, MJ2
Engler, K2
Routy, JP2
Jenabian, MA2
Kabengele, C1
M'hango, H1
Mweemba, D1
Malumani, M1
de Oliveira Alves, A1
Bortolato, T1
Bernardes Filho, F1
Gebhardt, A1
Fichtenbaum, CJ2
Gillard, BK2
Raya, JL1
Ruiz-Esponda, R1
Iyer, D1
Coraza, I2
Balasubramanyam, A2
Pownall, HJ2
Lin, C1
Grandinetti, A2
Shikuma, C2
Souza, S2
Parikh, N1
Nakamoto, B1
Kallianpur, KJ1
Chow, D1
Graziani, GM1
Trottier, B1
Sekhar, RV1
Dubé, MP2
Komarow, L1
Cadden, JJ1
Overton, ET1
Hodis, HN1
Currier, JS1
Stein, JH3
Tincati, C1
Savoldi, A1
Cannizzo, ES1
Bellistrì, GM1
Termini, R1
Garau, M1
Mancusi, D1
d'Arminio Monforte, A1
Marchetti, G1
Taylor, EW1
Chow, DC1
Seto, TB1
Mitchell, C1
Sriratanaviriyakul, N1
Gerschenson, M1
Shiramizu, B1
Oates, E1
Dzintars, K1
Wan, P1
Moat, S1
Anstey, A1
Grinspoon, S1
Fitch, K1
Wooten, JS1
Nambi, P1
Scott, LW1
Nambi, V1
Ballantyne, CM1
Fessel, WJ1
Follansbee, SE1
Rego, J1
Gerber, MT1
Mondy, KE1
Yarasheski, KE1
Drechsler, H1
Claxton, S1
Stoneman, J1
DeMarco, D1
Powderly, WG1
Tebas, P1
Currier, J1
Wu, JW1
Aberg, JA1
Deeg, MA1
Alston-Smith, BL1
McGovern, ME1
Lee, D1
Shriver, SL1
Martinez, AI1
Greenwald, M1
Tremeschin, MH1
Cervi, MC1
Camelo Júnior, JS1
Negrini, BV1
Martinez, FE1
Motta, F1
Meirelles, MS1
Vanucchhi, H1
Monteiro, JP1
Tang, AM1
Graham, NM1
Saah, AJ1
Gaucher, M1
Prabhu, D1
Dawe, RS1
Pitche, P1
Kombate, K1
Tchangai-Walla, K1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376]221 participants (Actual)Interventional2004-01-31Completed
Role of Extended-release Niacin on Immune Activation in HIV-infected Patients Treated With Antiretroviral Therapy: a Proof-of-concept Study[NCT02018965]Phase 216 participants (Actual)Interventional2011-11-30Completed
Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate[NCT01426438]Phase 299 participants (Actual)Interventional2011-11-30Completed
ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART[NCT01683656]Phase 44 participants (Actual)Interventional2012-08-31Terminated (stopped due to Withdrawal of IMP from the market. Data on risk-benefit ratio pending.)
Prospective Randomized Pilot Study of the Effect of Niaspan on Endothelial Function in HIV-infected Subjects With Low HDL Cholesterol Levels[NCT00986986]20 participants (Actual)Interventional2007-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

HDL-C

HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care37.1
Group 2 - Diet/Exercise Only38.7
Group 3 - Diet/Exercise + Fenofibrate40.7
Group 4 - Diet/Exercise + Niacin41.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin44.8

Non-HDL-C

non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care162.2
Group 2 - Diet/Exercise Only165.4
Group 3 - Diet/Exercise + Fenofibrate145.8
Group 4 - Diet/Exercise + Niacin154
Group 5 - Diet/Exercise + Fenofibrate + Niacin137.1

Total Cholesterol

Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care195.6
Group 2 - Diet/Exercise Only200.1
Group 3 - Diet/Exercise + Fenofibrate184
Group 4 - Diet/Exercise + Niacin190.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin178.4

Total Cholesterol : HDL-C Ratio

Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionratio (Mean)
Group 1 - Usual Care5.2
Group 2 - Diet/Exercise Only5.1
Group 3 - Diet/Exercise + Fenofibrate4.5
Group 4 - Diet/Exercise + Niacin4.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin4

Triglycerides

Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care199
Group 2 - Diet/Exercise Only216.9
Group 3 - Diet/Exercise + Fenofibrate155.1
Group 4 - Diet/Exercise + Niacin177.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin135.6

Body Composition

"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionkg (Mean)
Body cell massFat mass
Group 1 - Usual Care59.636.8
Group 2 - Diet/Exercise67.337.5
Group 3 - Diet/Exercise + Fenofibrate66.635.8
Group 4 - Diet/Exercise + Niacin67.137.7
Group 5 - Diet/Exercise + Fenofibrate + Niacin68.236.2

Insulin Sensitivity

Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionmicrograms/ml (Mean)
Fasting insulinHOMA-IRInsulin sensitvity indexAdiponectin
Group 1 - Usual Care8.71.923.547.12
Group 2 - Diet/Exercise Only6.71.384.956.04
Group 3 - Diet/Exercise + Fenofibrate9.52.023.815.24
Group 4 - Diet/Exercise + Niacin11.92.762.8811.01
Group 5 - Diet/Exercise + Fenofibrate + Niacin10.32.382.3810.34

Absolute Change in Relative FMD (%)

The absolute change in maximum relative flow mediated dilation (FMD) (%) of the brachial artery from baseline to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Intervention% FMD (Median)
Arm A: Extended-release Niacin With Aspirin0.60
Arm B: Fenofibrate0.50

Change in C-reactive Protein (CRP)

Change in C-reactive protein from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionug/ml (Median)
Arm A: Extended-release Niacin With Aspirin-0.6
Arm B: Fenofibrate0.7

Change in Cholesterol

Absolute change in total cholesterol from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-9
Arm B: Fenofibrate-2

Change in D-Dimer

Change in D-Dimer from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionug/ml (Median)
Arm A: Extended-release Niacin With Aspirin0.06
Arm B: Fenofibrate0.06

Change in HDL Particles

Change in total HDL particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionnmol/L (Median)
Arm A: Extended-release Niacin With Aspirin-1.7
Arm B: Fenofibrate4.3

Change in HOMA-IR

Absolute change from week 0 to week 24 in insulin resistance as estimated by HOMA-IR (NCT01426438)
Timeframe: 0 and 24 weeks

InterventionHOMA IR Score (Median)
Arm A: Extended-release Niacin With Aspirin1.3
Arm B: Fenofibrate0.3

Change in IL-6

Change in IL-6 from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionpg/ml (Median)
Arm A: Extended-release Niacin With Aspirin0.1
Arm B: Fenofibrate0.2

Change in Large HDL Particles

Change in Large HDL Particles from week 0 to week 24 (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionnmol/L (Median)
Arm A: Extended-release Niacin With Aspirin0.9
Arm B: Fenofibrate-0.3

Change in LDL Cholesterol

Change in LDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-1
Arm B: Fenofibrate7

Change in Non-HDL Cholesterol

Change in non-HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-17
Arm B: Fenofibrate-4

Change in Small LDL Particles

Change in Small LDL particles from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionnmol/L (Median)
Arm A: Extended-release Niacin With Aspirin-176
Arm B: Fenofibrate-119

Change in Triglycerides

Change in Triglycerides (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin-65
Arm B: Fenofibrate-54

Men: Change in HDL Cholesterol

Among men, change in HDL Cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin3
Arm B: Fenofibrate6.5

Women: Change in HDL Cholesterol

Among women, change in HDL cholesterol (mg/dL) from week 0 to week 24. (NCT01426438)
Timeframe: 0 and 24 weeks

Interventionmg/dL (Median)
Arm A: Extended-release Niacin With Aspirin16
Arm B: Fenofibrate8

Change in Flow-mediated Vasodilation (FMD) From Baseline to Study Week 12

Brachial arterial flow-mediated dilation (FMD), assessed by high-resolution ultrasonography, reflects endothelium-dependent vasodilator function. The primary outcome is the change in FMD from baseline to study week 12. (NCT00986986)
Timeframe: Two time points (baseline and study week 12)

Interventionpercentage change in FMD (Median)
Extended Release Niacin6.36
Observation2.73

Flow Mediated Vasodilation

Flow mediated vasodilation is a marker of endothelial function (NCT00986986)
Timeframe: 12 weeks

Interventionpercentage change in FMD (Median)
Active Drug (Extended Release Niacin)4.51
Observation3.25

High-density Lipoprotein Cholesterol (HDL) Change From Baseline to Study Week 12

"HDL, often referred to Good cholesterol levels, will be obtained in both arms. HDL is a marker of coronary heart disease." (NCT00986986)
Timeframe: Two time points (baseline and study week 12)

Interventionmg/dl (Median)
Active Drug (Extended Release Niacin)42.0
Observation27.0

Reviews

4 reviews available for niacin and HIV Coinfection

ArticleYear
Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:14

    Topics: Anti-Retroviral Agents; Drug Interactions; Dyslipidemias; Ezetimibe; HIV Infections; Humans; Hydroxy

2019
Treatment of dyslipidemia in HIV.
    Current atherosclerosis reports, 2015, Volume: 17, Issue:4

    Topics: Anti-HIV Agents; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diet Ther

2015
Pellagra: a review with emphasis on photosensitivity.
    The British journal of dermatology, 2011, Volume: 164, Issue:6

    Topics: Diet; Female; Genital Diseases, Female; Genital Diseases, Male; HIV Infections; Humans; Malabsorptio

2011
Pellagra a review exploring causes and mechanisms, including isoniazid-induced pellagra.
    Photodermatology, photoimmunology & photomedicine, 2021, Volume: 37, Issue:2

    Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Pel

2021

Trials

10 trials available for niacin and HIV Coinfection

ArticleYear
Impact of extended-release niacin on immune activation in HIV-infected immunological non-responders on effective antiretroviral therapy.
    HIV research & clinical practice, 2020, Volume: 21, Issue:6

    Topics: CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; HIV Infections; Humans

2020
Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function.
    Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:7

    Topics: Anti-Retroviral Agents; Biomarkers; Cell Line, Tumor; Cholesterol Esters; Combined Modality Therapy;

2013
The effects of extended release niacin on lipoprotein sub-particle concentrations in HIV-infected patients.
    Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, 2013, Volume: 72, Issue:4

    Topics: Adult; Delayed-Action Preparations; Female; HIV Infections; Humans; Hypolipidemic Agents; Lipoprotei

2013
The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.
    Trials, 2014, Oct-07, Volume: 15

    Topics: ADP-ribosyl Cyclase 1; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positi

2014
Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Sep-01, Volume: 61, Issue:5

    Topics: Adult; Brachial Artery; C-Reactive Protein; Cholesterol, HDL; Delayed-Action Preparations; Dyslipide

2015
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.
    AIDS (London, England), 2010, Apr-24, Volume: 24, Issue:7

    Topics: Antiretroviral Therapy, Highly Active; Brachial Artery; CD4 Lymphocyte Count; Cholesterol, HDL; Dela

2010
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.
    AIDS (London, England), 2010, Apr-24, Volume: 24, Issue:7

    Topics: Antiretroviral Therapy, Highly Active; Brachial Artery; CD4 Lymphocyte Count; Cholesterol, HDL; Dela

2010
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.
    AIDS (London, England), 2010, Apr-24, Volume: 24, Issue:7

    Topics: Antiretroviral Therapy, Highly Active; Brachial Artery; CD4 Lymphocyte Count; Cholesterol, HDL; Dela

2010
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.
    AIDS (London, England), 2010, Apr-24, Volume: 24, Issue:7

    Topics: Antiretroviral Therapy, Highly Active; Brachial Artery; CD4 Lymphocyte Count; Cholesterol, HDL; Dela

2010
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.
    Medicine and science in sports and exercise, 2013, Volume: 45, Issue:6

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Antiretroviral Therapy, Highly Active;

2013
High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution.
    AIDS (London, England), 2002, Sep-06, Volume: 16, Issue:13

    Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cholesterol, HDL; Cyclopro

2002
Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Aug-01, Volume: 39, Issue:3

    Topics: Antiretroviral Therapy, Highly Active; Cholesterol; Delayed-Action Preparations; Glucose Tolerance T

2004
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148.
    Antiviral therapy, 2006, Volume: 11, Issue:8

    Topics: Adult; Blood Glucose; Delayed-Action Preparations; Dyslipidemias; HIV Infections; Humans; Hypolipide

2006

Other Studies

13 other studies available for niacin and HIV Coinfection

ArticleYear
Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study.
    The Lancet. Global health, 2022, Volume: 10, Issue:5

    Topics: Antitubercular Agents; Case-Control Studies; Exanthema; Female; HIV Infections; Humans; Isoniazid; M

2022
A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report.
    The Pan African medical journal, 2021, Volume: 39

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Constipation; Dementia; Dermatitis; Female; HIV Infec

2021
Pellagra.
    The Journal of emergency medicine, 2018, Volume: 54, Issue:2

    Topics: Alcoholism; Diarrhea; Exudates and Transudates; HIV Infections; Humans; Ill-Housed Persons; Male; Mi

2018
T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study.
    Antiviral therapy, 2016, Volume: 21, Issue:2

    Topics: Adult; Anti-HIV Agents; Ascorbic Acid; Darunavir; Drug Combinations; Female; HIV Infections; HIV Pro

2016
The oxidative stress-induced niacin sink (OSINS) model for HIV pathogenesis.
    Toxicology, 2010, Nov-28, Volume: 278, Issue:1

    Topics: HIV Infections; HIV-1; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Models, Biological; Niacin; Oxi

2010
Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.
    The Annals of pharmacotherapy, 2010, Volume: 44, Issue:12

    Topics: Delayed-Action Preparations; Drug Interactions; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Pr

2010
Therapy: HIV-associated dyslipidemia: the heart positive study.
    Nature reviews. Endocrinology, 2011, Jun-21, Volume: 7, Issue:8

    Topics: Drug Therapy, Combination; Dyslipidemias; Exercise Therapy; Fenofibrate; Heart Diseases; HIV Infecti

2011
Report from the 7th International Lipodystrophy Meeting.
    AIDS clinical care, 2006, Volume: 18, Issue:1

    Topics: Anti-HIV Agents; Dyslipidemias; HIV Infections; Humans; Lipodystrophy; Niacin

2006
Side effects and complications. Extended-release high-dose niacin helps lower lipid levels.
    TreatmentUpdate, 2005, Volume: 17, Issue:7

    Topics: Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; CD4 Lymphocyte Count; Delayed-Action Pr

2005
Niacin nutritional status in HIV type 1-positive children: preliminary data.
    Journal of pediatric gastroenterology and nutrition, 2007, Volume: 44, Issue:5

    Topics: Cross-Sectional Studies; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; N

2007
Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection.
    American journal of epidemiology, 1996, Jun-15, Volume: 143, Issue:12

    Topics: Adult; Cohort Studies; Diet; HIV Infections; HIV-1; Humans; Male; Micronutrients; Niacin; Proportion

1996
Update on lipodystrophy.
    Positive Directions news : a support and information network of people with HIV/AIDS, their families, friends and providers, 1999,Winter, Volume: 11, Issue:1

    Topics: Diet; Disease Progression; Exercise; Female; HIV Infections; HIV Protease Inhibitors; Human Growth H

1999
[Prevalence of HIV infection in patients with pellagra and pellagra-like erythemas].
    Medecine tropicale : revue du Corps de sante colonial, 1999, Volume: 59, Issue:4

    Topics: Adolescent; Adult; Aged; Alcoholism; Cross-Sectional Studies; Erythema; Female; HIV Infections; HIV

1999
chemdatabank.com